MedPath
FDA Approval

CHLORZOXAZONE

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
September 5, 2023
Labeling Type
Human Prescription Drug Label
Chlorzoxazone(375 mg in 1 1)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

APL HEALTHCARE LIMITED

Aurobindo Pharma Limited

650844777

Products3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

CHLORZOXAZONE

Product Details

NDC Product Code
59651-305
Application Number
ANDA089853
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
September 5, 2023
Code: H0DE420U8GClass: ACTIBQuantity: 375 mg in 1 1
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT
STARCH, CORNInactive
Code: O8232NY3SJClass: IACT
DOCUSATE SODIUM/SODIUM BENZOATEInactive
Code: 656HXR6YXNClass: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61UClass: IACT
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48Class: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5XClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT

CHLORZOXAZONE

Product Details

NDC Product Code
59651-307
Application Number
ANDA089853
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
September 5, 2023
Code: H0DE420U8GClass: ACTIBQuantity: 750 mg in 1 1
STARCH, CORNInactive
Code: O8232NY3SJClass: IACT
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48Class: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5XClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
DOCUSATE SODIUM/SODIUM BENZOATEInactive
Code: 656HXR6YXNClass: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61UClass: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT

CHLORZOXAZONE

Product Details

NDC Product Code
59651-306
Application Number
ANDA089853
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
September 5, 2023
POLYSORBATE 80Inactive
Code: 6OZP39ZG8HClass: IACT
D&C RED NO. 27Inactive
Code: 2LRS185U6KClass: IACT
Code: H0DE420U8GClass: ACTIBQuantity: 500 mg in 1 1
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5XClass: IACT
FD&C YELLOW NO. 6Inactive
Code: H77VEI93A8Class: IACT
HYPROMELLOSE 2910 (3 MPA.S)Inactive
Code: 0VUT3PMY82Class: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61UClass: IACT
STARCH, CORNInactive
Code: O8232NY3SJClass: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2Class: IACT

Drug Labeling Information

Complete FDA-approved labeling information including indications, dosage, warnings, contraindications, and other essential prescribing details.

DESCRIPTION SECTION

DESCRIPTION

Each 375 mg chlorzoxazone tablet contains: Chlorzoxazone USP 375 mg.

Each 500 mg chlorzoxazone tablet contains: Chlorzoxazone USP 500 mg.

Each 750 mg chlorzoxazone tablet contains: Chlorzoxazone USP 750 mg.

Chemical Name: 5-Chloro-2-benzoxazolinone.

Structural Formula:

str

Molecular Formula: C7H4ClNO2

Molecular Weight: 169.56

Chlorzoxazone, USP is a white or practically white, practically odorless, crystalline powder. Chlorzoxazone USP is slightly soluble in water; sparingly soluble in alcohol, in isopropyl alcohol, and in methanol; soluble in solutions of alkali hydroxides and ammonia.

Inactive ingredients:

375 mg contains colloidal silicon dioxide, corn starch, croscarmellose sodium, docusate sodium with sodium benzoate, lactose monohydrate, magnesium stearate and microcrystalline cellulose.

500 mg contains D&C Red 27/Phloxine Aluminium lake, FD&C Yellow 6/Sunset Yellow FCF Aluminium lake, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polysorbate 80, pregelatinized starch, sodium starch glycolate.

750 mg contains colloidal silicon dioxide, corn starch, croscarmellose sodium, docusate sodium with sodium benzoate, lactose monohydrate, magnesium stearate and microcrystalline cellulose.

Meets USP dissolution test 5 for 500 mg.

FDA approved dissolution method differs from that of the USP for 375 mg and 750 mg.


© Copyright 2025. All Rights Reserved by MedPath